Clinical Trial Search

Primary: Number of Seroconverted Subjects for Measles, Mumps, Rubella, and Varicella Virus — 305; 162; 292; 151 Participants

Primary: Change in KAH Score for Children — 7.66; 3.76 units on a scale — p=<.001

Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes in the At Risk Primed Group. — 1.94; 6.16; 2.44; 3.66 μg/mL

Primary: Adjunct Study Arm: Compare Assay Performance for Aptima HPV Assay to a FDA-Approved HPV Assay for Detecting CIN2+ — 15; 5; 299; 500 participants

Primary: Change in TEWL at Top of Outer Lower Legs — 12.74; 13.43; 13.52; 13.27 g/m2/h — p=<0.001

Primary: Endurance Time During Endurance Shuttle Walk Test (ESWT) to Symptom Limitation After 8 Weeks — 244.07; 254.18; 315.32; 355.73 Second — p=0.0002

Primary: Number of Subjects With Anti-Glycoprotein E (Anti-gE) Antibody Concentrations Higher Than or Equal to (≥)18 Milli-international Units Per Milliliter (mIU/mL) — 29; 29…

Primary: Number of Participants With Clinical Response at Week 6 — 60; 108; 116 participants — p=< 0.001

Primary: Vaccine Pneumococcal Serotype Antibody Concentrations — 0.14; 0.38; 0.16; 1.35 μg/mL

Primary: Median Progression Free Survival (PFS) — 19.35; 14.85 Months — p=0.0014

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus - Type 1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 400 Copies Per Milliliter (Copies/mL) at…

Primary: Local Tolerability (Erythema) — 149; 64; 5 participants

Primary: Cardiac Stress Test: Time to ST Depression — 439.1; 279.5; 364.0; 292.6 seconds — p=0.03

Primary: Tolerability Survey Score Using a 100 Unit Visual Analog Scale (VAS) in Period 1 — 255.74; 280.17; 284.89; 255.83 score on a scale

Primary: Negative Predictive Value — 98.0 percentage of participants